See more : IOI Corporation Berhad (IOIOF) Income Statement Analysis – Financial Results
Complete financial analysis of Aldeyra Therapeutics, Inc. (ALDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aldeyra Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PrimeEnergy Resources Corporation (PNRG) Income Statement Analysis – Financial Results
- MRS Logística S.A. (MRSA6B.SA) Income Statement Analysis – Financial Results
- Moriroku Holdings Company, Ltd. (4249.T) Income Statement Analysis – Financial Results
- Shenzhen Desay Battery Technology Co., Ltd. (000049.SZ) Income Statement Analysis – Financial Results
- EJF Investments Limited (EJFI.L) Income Statement Analysis – Financial Results
Aldeyra Therapeutics, Inc. (ALDX)
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -262.78K | -258.71K | -264.18K | -56.22K | -96.31K | -71.00K | -37.85K | -35.79K | -18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.46M | 47.31M | 44.94M | 24.68M | 44.35M | 29.82M | 16.30M | 13.18M | 7.57M | 3.71M | 1.54M | 469.27K | 1.36M |
| General & Administrative | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.33M | 720.79K | -21.48M | 5.41K |
| Operating Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Cost & Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Interest Income | 7.32M | 2.35M | 185.36K | 292.22K | 1.54M | 952.70K | 261.25K | 102.04K | 11.13K | 3.00 | 31.00 | 101.00 | 5.00K |
| Interest Expense | 2.07M | 1.69M | 1.74M | 1.90M | 603.85K | 146.79K | 113.45K | 105.51K | 112.31K | 244.17K | 159.32K | 342.01K | 279.93K |
| Depreciation & Amortization | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 1.07K | 31.00 | 3.74K | 1.59K |
| EBITDA | -35.21M | -60.07M | -55.77M | -36.07M | -61.44M | -38.68M | -22.19M | -18.56M | -11.96M | -4.94M | 13.22M | -22.73M | -2.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.79M | -62.68M | -56.22M | -36.42M | -63.07M | -39.70M | -22.49M | -18.70M | -11.99M | -7.27M | -3.68M | -1.11M | -2.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.25M | 655.35K | -1.56M | -3.37M | -5.63M | 805.91K | 147.80K | -3.47K | -101.18K | 2.08M | 16.74M | -21.96M | -269.53K |
| Income Before Tax | -37.54M | -62.02M | -57.78M | -38.03M | -62.14M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -655.35K | 1.48M | -479.27K | -1.31M | 952.70K | 223.40K | 66.25K | -7.65K | 243.11K | 159.29K | -21.14M | 285.34K |
| Net Income | -37.54M | -61.37M | -59.25M | -37.55M | -60.83M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 | 39.90 | -5.72 | -7.26 |
| EPS Diluted | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.35 | 2.72 | -5.10 | -0.50 |
| Weighted Avg Shares Out | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 327.37K | 4.04M | 327.37K |
| Weighted Avg Shares Out (Dil) | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 4.80M | 4.52M | 4.80M |
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES , Sept. 11, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023
NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Attention Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ: ALDX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 17, 2022 and...
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 10, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX
NEW YORK , Sept. 9, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities lawsuit.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
Source: https://incomestatements.info
Category: Stock Reports